Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoSTU:KY4 +1.42%84 Market Cap is €7,504 Mil as of Jul. 13, 2026. GuruFocus rates STU:KY4 with a GF Score™ of 84/100 and a GF Value™ of €15.89 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,024 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 94.24% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kyowa Kirin Co's share price for the quarter that ended in Dec. 2025 was €13.6. Kyowa Kirin Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 523 Mil. Therefore, Kyowa Kirin Co's market cap for the quarter that ended in Dec. 2025 was €7,119 Mil.
Kyowa Kirin Co's quarterly market cap
declined
from Jun. 2025 (€7,486 Mil) to Sep. 2025 (€6,805 Mil) but then
increased
from Sep. 2025 (€6,805 Mil) to Dec. 2025 (€7,119 Mil).
Kyowa Kirin Co's annual market cap
declined
from Dec. 2023 (€8,064 Mil) to Dec. 2024 (€7,484 Mil) and
declined
from Dec. 2024 (€7,484 Mil) to Dec. 2025 (€7,119 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kyowa Kirin Co's Enterprise Value for Today is €6,144 Mil.
Kyowa Kirin Co (STU:KY4) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kyowa Kirin Co Market Cap Related Terms
Kyowa Kirin Co Market Cap Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Kyowa Kirin Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (STU:KY4) has a Market Cap of €7,504 Mil as of Jul. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kyowa Kirin Co and its competitors. According to the industry distribution chart, Kyowa Kirin Co ranks #59 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 5.8%.
Is Kyowa Kirin Co's Market Cap too high?
Kyowa Kirin Co's current Market Cap is €7,504 Mil. Based on the distribution chart, Kyowa Kirin Co ranks #59 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #59 out of 1024 companies for Market Cap. This places Kyowa Kirin Co in the top 6% of its industry — outperforming the majority of peers. The industry median Market Cap is 212.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 212.63, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 212.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Market Cap is €7,504 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (STU:KY4) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.89, compared to a current price of €14.30 — trading 10% below its estimated fair value. The current Market Cap is €7,504 Mil. Kyowa Kirin Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kyowa Kirin Co (STU:KY4), the current Market Cap is €7,504 Mil as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (STU:KY4) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of €14.30 is trading 10% below its estimated GF Value™ of €15.89.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for STU:KY4:
Market Cap: €7,504 Mil
GF Value™: €15.89 vs. price of €14.30 (10% below fair value)
No single metric tells the full story. See the STU:KY4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
84GF Score
Get the complete analysis for STU:KY4
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:KY4 has been successfully added to your 
